logo
Share SHARE
FONT-SIZE Plus   Neg

Alnylam Pharmaceuticals Inc. (ALNY) Has Jumped To A New High On Study Results

Alnylam Pharmaceuticals Inc. (ALNY) and Sanofi Genzyme announced Wednesday morning that their Phase 3 study of patisiran, in patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary endpoint and all secondary endpoints.

Alnylam Pharmaceuticals has gapped open dramatically higher this morning and is now up 24.33 at $99.37 on above average volume. The stock has surged to a new high for the year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT